fluoxetine has been researched along with adenosine monophosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cedeño, N; Fazzino, F; Lima, L; Urbina, M | 1 |
| Brunotte, L; Ludwig, S; Mecate-Zambrano, A; Rescher, U; Schloer, S; Tang, J; Zheng, S | 1 |
2 other study(ies) available for fluoxetine and adenosine monophosphate
| Article | Year |
|---|---|
Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4+ and CD8+ subpopulations and interleukins 2 and 4.
Topics: Adenosine Monophosphate; Animals; Antidepressive Agents, Second-Generation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Fluoxetine; Immunologic Factors; Interleukin-2; Interleukin-4; Male; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2009 |
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Fluoxetine; Hepatitis C, Chronic; Humans; Itraconazole; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |